Diaminothiazole compounds, pharmaceutically acceptable prodrug, pharmaceutically active metabolite or pharmaceutically acceptable salt, pharmaceutical composition, method of treating a mammalian disease condition mediated by protein kinase activity and method of modulating the activity of a kinase receptor on protein

摘要

"DIAMINOTIAZOL COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE PRO-DRUGS, PHARMACEUTICALLY ACTIVE METABOLITE OR PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION, METHOD OF TREATING A STATEMENT OF EFFECTIVENESS OF HAZARDOUS TREATMENT. PROTEIN ". The present invention relates to diaminothiazole compounds of Formula (1) that modulate and / or inhibit the activity of certain protein kinases. These compounds and pharmaceutical compositions containing them are able to mediate tyrosine kinase signal transduction in order to modulate and / or inhibit unwanted cell proliferation. The invention also relates to the prophylactic or therapeutic use of these compounds and compositions and methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and cell proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis and psoriasis, through administration of effective amounts of these compounds.